You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
Siemens Healthineers will use the technology, which Quanterix acquired as part of its buy of UmanDiagnostics, to develop blood-based Nf-L clinical tests.
Acquired epilepsy is a form of the neurological disorder that results from other conditions such as stroke, infections, and traumatic brain injury.
The organizations noted in a letter to HHS and FDA that they "believe the agency's actions may in fact inflict greater harm on patients and impede innovation."
The blood-based test is designed to detect changes in levels of microRNAs that are enriched in specific brain regions affected by Alzheimer's disease.
The team aims to fully commercialize the 28-biomarker panel for military veterans and civilians who show early symptoms of post-traumatic stress disorder.
A recent study from UCSF suggests Abbott's blood-based i-Stat Alinity device may be able to identify TBI that isn't found by a CT scan.
The firm said that its rapid point-of-care test enables immediate drug adjustments by measuring levels of clozapine, an antipsychotic drug, in a finger prick of blood.
The firm said that its lateral flow test may enable sports teams and paramedics to quickly decide whether there's a concussion or not.
The company provided updates on its newborn screening testing presence.
The financing, led by Accelerated Digital Ventures, will go toward the development of 20 tests targeted at cancers and dementias.
The company expects the rollout of more reliable, user-friendly platforms will increase instrument usage among a substantial segment of its customer base.
When blood amyloid levels are combined with other risk factors, people with early Alzheimer's brain changes can be identified with high accuracy.
The firm will use the proceeds to continue developing its Proteograph platform, build its proteomic database, and develop liquid biopsy products for early disease detection.
The group will start a pilot study at Columbia University next week to sequence genes from 600 Parkinson's disease patients before expanding to a larger cohort.
Fulgent will use its Parkinson's disease NGS panel to target seven genes linked to the condition and generate curated reports for doctors and researchers.
Within the "Big Three" conditions, misdiagnoses related to stroke, sepsis, and lung cancer accounted for the most high-severity diagnostic error cases.
The Elisabeth Severance Prentiss Foundation gift will expand research into the use of saliva to monitor lithium levels in patients with bipolar and other disorders.
The firm is validating a mild TBI biomarker-based diagnostic kit for use by paramedics, first responders, and other healthcare professionals.
A combination of three biomarkers accurately predicted abnormal accumulation of beta-amyloid plaques in the brains of living Alzheimer's disease patients.